Caribou Biosciences (CRBU) Return on Sales (2020 - 2025)
Caribou Biosciences (CRBU) has disclosed Return on Sales for 6 consecutive years, with 10.66% as the latest value for Q4 2025.
- On a quarterly basis, Return on Sales rose 805.0% to 10.66% in Q4 2025 year-over-year; TTM through Dec 2025 was 10.66%, a 601.0% increase, with the full-year FY2024 number at 14.92%, down 1196.0% from a year prior.
- Return on Sales was 10.66% for Q4 2025 at Caribou Biosciences, up from 13.38% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.62% in Q3 2023 to a low of 18.94% in Q1 2024.
- A 5-year average of 10.67% and a median of 9.29% in 2021 define the central range for Return on Sales.
- Peak YoY movement for Return on Sales: crashed -1827bps in 2024, then surged 805bps in 2025.
- Caribou Biosciences' Return on Sales stood at 7.22% in 2021, then decreased by -15bps to 8.28% in 2022, then dropped by -27bps to 10.52% in 2023, then tumbled by -78bps to 18.72% in 2024, then skyrocketed by 43bps to 10.66% in 2025.
- Per Business Quant, the three most recent readings for CRBU's Return on Sales are 10.66% (Q4 2025), 13.38% (Q3 2025), and 17.84% (Q2 2025).